Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 6/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.49 |
| ▸ | RORC | P51449 | 8/20 | 0.45 |
| ▸ | RORB | Q92753 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943898 | 0.91 | RORA (0.53) | RORANR1H3RORCRORBNR1H2 | |
| SCHEMBL11424113 | 0.85 | RORA (0.56) | RORANR1H3RORCRORBNR1H2 | |
| SCHEMBL2940775 | 0.82 | RORA (0.50) | RORANR1H3RORCRORBNR1H2 | |
| SCHEMBL2944332 | 0.80 | NR1H3 (0.66) | RORANR1H3RORCRORBNR1H2 | |
| SCHEMBL4427665 | 0.75 | NR1H2 (0.55) | NR1H3RORCNR1H2SMN1; SMN2MLYCD | |
| Hydrochloric Acid SCHEMBL4881350 | 0.74 | NR1H2 (0.54) | NR1H3RORCNR1H2SMN1; SMN2MLYCD | |
| SCHEMBL29124111 | 0.74 | PPARA (0.55) | SMN1; SMN2CA1CA2EPHX1PPARA | |
| SCHEMBL11412249 | 0.74 | RORA (0.63) | RORANR1H3RORCRORBNR1H2 | |
| SCHEMBL2940660 | 0.72 | RORA (0.55) | RORANR1H3RORCRORBNR1H2 | |
| SCHEMBL18893587 | 0.72 | NR1H3 (0.56) | RORANR1H3RORCNR1H2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | RORA 2055/4885NR1H3 1227/4885RORC 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.